Back to Search
Start Over
The miR-17-92 cluster counteracts quiescence and chemoresistance in a distinct subpopulation of pancreatic cancer stem cells.
- Source :
-
Gut [Gut] 2015 Dec; Vol. 64 (12), pp. 1936-48. Date of Electronic Publication: 2015 Apr 17. - Publication Year :
- 2015
-
Abstract
- Objective: Cancer stem cells (CSCs) represent the root of many solid cancers including pancreatic ductal adenocarcinoma, are highly chemoresistant and represent the cellular source for disease relapse. However the mechanisms involved in these processes still need to be fully elucidated. Understanding the mechanisms implicated in chemoresistance and metastasis of pancreatic cancer is critical to improving patient outcomes.<br />Design: Micro-RNA (miRNA) expression analyses were performed to identify functionally defining epigenetic signatures in pancreatic CSC-enriched sphere-derived cells and gemcitabine-resistant pancreatic CSCs.<br />Results: We found the miR-17-92 cluster to be downregulated in chemoresistant CSCs versus non-CSCs and demonstrate its crucial relevance for CSC biology. In particular, overexpression of miR-17-92 reduced CSC self-renewal capacity, in vivo tumourigenicity and chemoresistance by targeting multiple NODAL/ACTIVIN/TGF-β1 signalling cascade members as well as directly inhibiting the downstream targets p21, p57 and TBX3. Overexpression of miR-17-92 translated into increased CSC proliferation and their eventual exhaustion via downregulation of p21 and p57. Finally, the translational impact of our findings could be confirmed in preclinical models for pancreatic cancer.<br />Conclusions: Our findings therefore identify the miR-17-92 cluster as a functionally determining family of miRNAs in CSCs, and highlight the putative potential of developing modulators of this cluster to overcome drug resistance in pancreatic CSCs.<br /> (Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/)
- Subjects :
- Activins metabolism
Animals
Antimetabolites, Antineoplastic therapeutic use
Carcinoma, Pancreatic Ductal drug therapy
Carcinoma, Pancreatic Ductal genetics
Cell Cycle Checkpoints drug effects
Cell Self Renewal
Cell Transformation, Neoplastic
Cyclin-Dependent Kinase Inhibitor p21 genetics
Cyclin-Dependent Kinase Inhibitor p21 metabolism
Cyclin-Dependent Kinase Inhibitor p57 metabolism
Deoxycytidine pharmacology
Deoxycytidine therapeutic use
Down-Regulation
Epigenesis, Genetic
Female
Gene Expression Regulation, Neoplastic
Gene Knockdown Techniques
Humans
Mice
Mice, Nude
MicroRNAs antagonists & inhibitors
MicroRNAs genetics
Neoplastic Stem Cells drug effects
Nodal Protein metabolism
Pancreatic Neoplasms drug therapy
Pancreatic Neoplasms genetics
RNA, Long Noncoding
Signal Transduction
T-Box Domain Proteins genetics
T-Box Domain Proteins metabolism
Transcriptome
Transforming Growth Factor beta1 metabolism
Gemcitabine
Antimetabolites, Antineoplastic pharmacology
Carcinoma, Pancreatic Ductal metabolism
Deoxycytidine analogs & derivatives
Drug Resistance, Neoplasm genetics
MicroRNAs metabolism
Neoplastic Stem Cells metabolism
Pancreatic Neoplasms metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1468-3288
- Volume :
- 64
- Issue :
- 12
- Database :
- MEDLINE
- Journal :
- Gut
- Publication Type :
- Academic Journal
- Accession number :
- 25887381
- Full Text :
- https://doi.org/10.1136/gutjnl-2014-308470